

Arguments/ Remarks

Claims 108-115, 123, 131-136 are pending. Claims 112-113, 115, 125-130 have been withdrawn in light of the prior issued restriction requirement. Claims 1-107 and 116-122, 124 have been cancelled. Accordingly, claims 108-111, 114, 123, 131-136 are presently pending and under Examination. All claims stand free of the art.

Applicants have previously elected, for purposes of initial Examination, the hybridoma species 1F2 having ATCC accession no. PTA-5959. Applicants prior-filed Replay to the Official Action of November 30, 2007, provided a Verified Statement of co-inventor Maria Concetta Veri establishing the facts of this Deposit.

Applicants have requested rejoinder of the withdrawn claims and consideration of the Allowability of the full scope of the presented claims. In order to advance prosecution of such scope, Applicants herewith submit a Verified Statement of co-inventor Maria Concetta Veri establishing the facts of the deposits of the four additional clones recited in the claims:

1. Clone 1D5 having ATCC Accession No. PTA-5958;
2. Clone 2E1 having ATCC Accession No. PTA-5961;
3. Clone 2H9 having ATCC Accession No. PTA-5962; and
4. Clone 2D11 having ATCC Accession No. PTA-5960.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. §121. The Application is believed to be in condition for further Examination and early notice of favorable action is respectfully requested.

In Re Patent Appln. of
Scott Koenig and Marie Concetta Veri
Serial No. 10/0643,857

Reply to the Official Action of November 30, 2007
Page 3

Should the Examiner have any remaining questions regarding the subject invention or its patentability, Applicants encourage the Examiner to contact the undersigned.

Respectfully Submitted,

Date: **March 4, 2008**
Edell, Shapiro & Finn, LLC
1901 Research Boulevard, Suite 400
Rockville, MD 20850
Telephone: (301) 424-3640
Facsimile: (301) 762-4056

/Jeffrey I. Auerbach/
Jeffrey I. Auerbach
Registration No. 32,680
Attorney for Assignee

Customer No. **66522**

In The United States Patent and Trademark Office

In re application of:
Koenig, Scott et al.

Appl. No. **10/643,857**

Filed: **August 14, 2003**

For: **FcγRIIB-Specific Antibodies
and Methods of Use Thereof**

Art Unit: **1644**

Examiner: **Dahle, Chun Wu**

Atty. Docket: **1301.0019C**

Confirmation No.: **1191**

Second Verified Statement of Maria Concetta Veri

Filed via EFS-Web
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Maria Concetta Veri, hereby declare:

1. I am a co-inventor of the invention claimed in the above-described patent application, and have personal knowledge of the matters related in this Declaration.
2. On February 28, 2008, I submitted a Verified Statement relating to the Deposit of the hybridoma cell lines **1F2** (ATCC Accession No. PTA-5959). I make this Second Verified Statement to address the Deposits of the hybridoma cell lines: **1D5, 2D11, 2E1** and **2H9**, which are described in the above-identified patent application.
3. Each of the hybridoma cell lines: **1D5, 2D11, 2E1** and **2H9**, which are described in the above-identified patent application were produced prior to the filing date of the above-identified patent application.

4. On May 4, 2004, I deposited each of the hybridoma cell lines **1D5, 2D11, 2E1 and 2H9** with the American Type Culture Collection (ATCC) under the terms of the Budapest Treaty. I have enclosed a copy of the original Deposit Forms as evidence of the May 4, 2004 deposit. The deposited hybridomas were found to be viable by the ATCC and were accorded ATCC Accession Nos.: PTA-5958 (cell line **1D5**); PTA-5960 (cell line **2D11**); PTA-5961 (cell line **2E1**); and PTA-5962 (cell line **2H9**). I enclose the certificate of viability for these cell lines and for PTA-5959 (cell line **1F2**).
5. From a time prior to the filing date of the above-identified patent application to May 4, 2004, each of the hybridoma cell lines **1D5, 2D11, 2E1 and 2H9** were kept under my personal supervision and control in a liquid nitrogen freezer. To my knowledge no other person accessed these cell lines during this period.
6. Each of the hybridoma cell lines: **1D5, 2D11, 2E1 and 2H9**, which are described in the above-identified patent application is the same cell line that was deposited with the American Type Culture Collection on May 4, 2004 and accorded ATCC Accession Nos.: PTA-5958 (cell line **1D5**); PTA-5960 (cell line **2D11**); PTA-5961 (cell line **2E1**); and PTA-5962 (cell line **2H9**).
7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

In Re Patent Appln. of
Scott Koenig and Marie Concetta Veri
Serial No. 10/0643,857

2nd Verified Statement of Maria Concetta Veri
Page 3 of 3

Code and that such willful false statements may jeopardize the validity of
the application or any patent issued thereon.

Maria Concetta Veri

Maria Concetta Veri

March 4, 2008

Date



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection
P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- Microorganism – the complete scientific name including genus and species plus the source of the material
- Virus – the name, whether plant or animal, and source including geographic location
- Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
- Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
- Consortia or mixed culture – the identity of each component of the mixture
- Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

HYBRIDOMA Fc_γRIIA TRANSGENIC MICE WERE IMMUNIZED WITH MAMMALIAN EXPRESSED EXTRACELLULAR PORTION OF Fc_γRIIB. LYMPHOCYTES FROM THE IMMUNIZED MICE WERE FUSED WITH HL-1 MYELOMA CELLS TO IMMORTALIZE THE

2. Strain designation* (i.e., number, symbols, etc). 1D5

*The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? Yes No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?

Yes No

If yes, please indicate ATCC designation. _____

5. Is this deposit a mixture of microorganisms or cells? Yes No
If yes, please describe: _____

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DULBECCO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL CALF SERUM, 2mM GLUTAMINE AND 500U/ml GENTAMICIN. CELLS HAVE BEEN FROZEN (0.10⁶ CELLS/VIAL) IN FETAL CALF SERUM CONTAINING 10% DMSO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS.

a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? Yes No
If yes, please list the antibiotics: GENTAMICIN (50U/ml)

b. If deposit is a hybridoma, what is the isotype of the antibody produced? monoclonal IgG1

8. Safety: Is this strain hazardous to humans? NO Animals? NO Plants? NO

If yes, what is the recommended biosafety level for working with this strain?

(Refer to *Biosafety in Microbiological and Biomedical Laboratories*, 4th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC; U.S. Government Printing Office; 1999. The entire text is available online at www.cdc.gov/od/ohs/biosfty/bmb14/bmb14toc.htm.)

9. Regulatory Compliance:

a. Was the material derived from a human? Yes No
 If yes, was an IRB-approved consent form (human subjects) obtained? Yes No

b. Was this material obtained from wildlife? Yes No
 If yes, please indicate genus and species and whether wild or captive bred.

c. Is work performed at your facility with exotic viruses affecting livestock and avian species? Yes No

d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED - ORIGIN: UNITED STATES. MYCOPLASMA, VIRUS, BACTERIOPHAGE AND ENDOTOXIN TESTED (INVITROGEN CORPORATION)

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. Yes No

b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? Yes No
 If "yes," please state which countries:

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 (e)(2)).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Panigot
 Fax 301-251-5321 Phone: 301-354-0686 E-mail: panigotj@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____ Check No. _____

Credit Card number. _____ MasterCard VISA American Express

Exp. Date: _____ Name shown on card: _____
 (Please print clearly or type)

Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Maracic

Billing Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6702

Phone: (212) 790-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? Yes No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Geraldine F. Baldwin, Esq.
Jones Day, 222 E. 41st Street
New York, NY 10017-6702 (Ref: Docket or Case No. 11183-013-999)

14. **MUST BE COMPLETED.** Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Panigot Joseph Z. Panigot 5/4/04
 Printed Name Signature Date

Address: MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850

Phone: (301) 354-0686 Fax (301) 851-5321 E-mail: panigot@macrogenics.com

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax: (703) 365-2745
 E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION _____ REC'D _____ V.T. RESULT _____

ATCC® is a registered trademark of the American Type Culture Collection.



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection
P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- Microorganism – the complete scientific name including genus and species plus the source of the material
- Virus – the name, whether plant or animal, and source including geographic location
- Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
- Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
- Consortia or mixed culture – the identity of each component of the mixture
- Seeds, embryos, Insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

LYBRIDOMA. EGFR II A TRANSGENIC MICE WERE IMMUNIZED WITH HUMAN
EXPRESSED EXTRACELLULAR PORTION OF EGFR II B. LYMPHOCYTES FROM
THE IMMUNIZED MICE WERE FUSED WITH HL-1 MYELOMA CELLS TO IMMORTALIZE.

2. Strain designation* (i.e., number, symbols, etc). 2D11

*The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? Yes No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?

Yes No

If yes, please indicate ATCC designation. _____

5. Is this deposit a mixture of microorganisms or cells? Yes No

If yes, please describe: _____

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DULBECCO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL
CALF SERUM, 2mM GLUTAMINE AND 50μg/ml GENTAMICIN. CELLS
HAVE BEEN FROZEN (10 · 10⁶ cells/vial) IN FETAL CALF SERUM CONTAINING
10% DMSO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS

a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? Yes No

If yes, please list the antibiotics: GENTAMICIN (50 μg/ml)

b. If deposit is a hybridoma, what is the isotype of the antibody produced? IgG1

8. Safety: Is this strain hazardous to humans? NO Animals? NO Plants? NO

If yes, what is the recommended biosafety level for working with this strain? _____
 (Refer to *Biosafety in Microbiological and Biomedical Laboratories*, 4th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC; U.S. Government Printing Office, 1999. The entire text is available online at www.cdc.gov/od/abs/biosfty/bmbl4/bmb4toc.htm.)

9. Regulatory Compliance:

a. Was the material derived from a human? Yes No
 If yes, was an IRB-approved consent form (human subjects) obtained? Yes No

b. Was this material obtained from wildlife? Yes No
 If yes, please indicate genus and species and whether wild or captive bred. _____

c. Is work performed at your facility with exotic viruses affecting livestock and avian species? Yes No

d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED ORIGIN : UNITED STATES.
MYCOPLASMA VIRUS BACTERIOPHAGE AND ENDOTOXIN TESTED
(INVITROGEN CORPORATION).

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. Yes No

b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? Yes No
 If "yes," please state which countries: _____

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a][2]).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Paniget
 Fax 301-251-5321 Phone: 301-354-0686 E-mail: paniget@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____ Check No. _____

Credit Card number: _____ MasterCard VISA American Express

Exp. Date: _____ Name shown on card: _____
 (Please print clearly or type)

Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Marack

Billing Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6703

Phone: (212) 790-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? Yes No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Geraldine F. Baldwin, Esq.
Jones Day, 222 E. 41st Street
New York, NY 10017-6702 (Ref: Docket or Case No. 11(83-013-999))

14. **MUST BE COMPLETED.** Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Panigot Joseph E. Panigot 5/4/04
 Printed Name Signature Date

Address: MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850

Phone: (301) 354-0686 Fax (301) 351-5321 E-mail: panigotj@macrogenics.com

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax: (703) 365-2745
 E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION _____ REC'D _____ V.T. RESULT _____

ATCC® is a registered trademark of the American Type Culture Collection.



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection
P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- Microorganism – the complete scientific name including genus and species plus the source of the material
- Virus – the name, whether plant or animal, and source including geographic location
- Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
- Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
- Consortia or mixed culture – the identity of each component of the mixture
- Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

HYBRIDOMA. F₁ RIIA TRANSGENIC MICE WERE IMMUNIZED WITH MAMMALIAN EXPRESSED EXTRACELLULAR PORTION OF THE RIBB. LYMPHOCYTES FROM THE IMMUNIZED MICE WERE FUSED WITH HL-1 MYELOMA CELLS TO IMMORTALIZE THEM.

2. Strain designation* (i.e., number, symbols, etc). 2E1

*The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? Yes No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?

Yes No

If yes, please indicate ATCC designation. _____

5. Is this deposit a mixture of microorganisms or cells? Yes No

If yes, please describe: _____

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DULBECCO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL CALF SERUM, 2 mM GLUTAMINE AND 50 μg/ml GENTAMICIN. CELLS HAVE BEEN FROZEN (10. 10⁶ cells/vial) IN FETAL CALF SERUM CONTAINING 10% DMSO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS

a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? Yes No
If yes, please list the antibiotics: GENTAMICIN (sugamycin)

b. If deposit is a hybridoma, what is the isotype of the antibody produced? murine IgG1

8. Safety: Is this strain hazardous to humans? No Animals? No Plants? No

If yes, what is the recommended biosafety level for working with this strain?

(Refer to *Biosafety in Microbiological and Biomedical Laboratories*, 4th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control, Washington, DC; U.S. Government Printing Office; 1999. The entire text is available online at www.cdc.gov/nid/dhs/biosfty/bmbl4/bmbl4toc.htm.)

9. Regulatory Compliance:

a. Was the material derived from a human? Yes No
 If yes, was an IRB-approved consent form (human subjects) obtained? Yes No

b. Was this material obtained from wildlife? Yes No
 If yes, please indicate genus and species and whether wild or captive bred.

c. Is work performed at your facility with exotic viruses affecting livestock and avian species? Yes No

d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED, ORIGIN: UNITED STATES, Mycoplasma, VIRUS, BACTERIOPHAGE AND ENDOTOXIN TESTED (INNITROGEN CORPORATION)

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. Yes No

b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? Yes No
 If "yes," please state which countries:

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a][2]).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Panigot

Fax: 301-251-5321 Phone: 301-354-0686 E-mail: panigotj@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____

Check No. _____

Credit Card number. _____

MasterCard VISA American Express

Exp. Date: _____

Name shown on card: _____
 (Please print clearly or type)

Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Marack

Billing Address: Jones Day, 222 E. 41st Street

New York, NY 10017-6703

Phone: (212) 790-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? Yes No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Geraldine F. Baldwin, Esq.
Jones Day, 222 E. 41st Street
New York, NY 10017-6702 (Ref: Docket or Case No. 11183-013-999)

14. MUST BE COMPLETED. Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Panigot Joseph E. Panigot 5/4/04
 Printed Name Signature Date

Address: MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850

Phone: (301) 354-0686 Fax (301) 251-5321 E-mail: panigotj@macrogenics.co

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax: (703) 366-2745
 E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 366-2745.

ATCC USE ONLY: ATCC DESIGNATION _____ REC'D _____ V.T. RESULT _____

ATCC® is a registered trademark of the American Type Culture Collection.



BUDAPEST TREATY DEPOSIT FORM (BP/1)

American Type Culture Collection
P.O. Box 1549
Manassas, VA 20108

TO DEPOSIT OR TO CONVERT A DEPOSIT TO MEET THE REQUIREMENTS OF THE BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF A PATENT PROCEDURE

ALL QUESTIONS MUST BE COMPLETED IN ENGLISH. PLEASE USE ONE FORM FOR EACH STRAIN DEPOSITED.

1. Name of deposit. Please mark the appropriate box and provide the information requested for the material:

- Microorganism – the complete scientific name including genus and species plus the source of the material
- Virus – the name, whether plant or animal, and source including geographic location
- Cell line – the species and tissue of origin, geographical source of isolation, and any known associated hazards (HIV, EBV, etc.)
- Genetic material – the name of organism from which vector, clone or library is derived, the source of the DNA insert identified by species (e.g., human, mouse) or scientific name, the name of gene, and the identity of the host organism
- Consortia or mixed culture – the identity of each component of the mixture
- Seeds, embryos, insect eggs, etc. – the common name, the scientific name of the source of the deposit, and geographical source

HYBRIDOMA Fc_γ RIIA TRANSGENIC MICE LIPSE IMMUNIZED WITH MAMMALIAN EXPRESSED EXTRACELLULAR PORTION OF Fc_γ RTIB. LYMPHOCYTES FROM THE IMMUNIZED MICE WERE FUSED WITH HL1 MYELOMA CELLS TO IMMORTALIZE THEM.

2. Strain designation* (i.e., number, symbols, etc). 2H9

*The strain designation must correspond with the vial labels.

3. Is this an original deposit under the Budapest Treaty? Yes No

4. Is this a request for a conversion of a deposit already at the ATCC to meet the requirements of the Budapest Treaty?

Yes No

If yes, please indicate ATCC designation.

5. Is this deposit a mixture of microorganisms or cells? Yes No

If yes, please describe:

6. Provide details necessary to cultivate, test for viability and store the deposit. If a mixture, provide description of components and a method to check for presence. If a plasmid, provide name of host and antibiotic resistance.

DULBECCO'S MODIFIED EAGLE MEDIUM SUPPLEMENTED WITH 15% FETAL Calf SERUM, 2 mM GLUTAMINE AND 50 µg/ml of GENTAMICIN. CELLS HAVE BEEN FROZEN (10·10⁶ CELLS/VIAL) IN FETAL Calf SERUM CONTAINING 10% OF DM SO AND PLACED IN LIQUID NITROGEN.

7. Provide sufficient description so that ATCC may confirm deposit properties (e.g., Gram negative rod).

ADHERENT CELLS

a. If deposit is a cell culture, is it being cultured in the presence of antibiotics? Yes No

If yes, please list the antibiotics: GENTAMICIN (50 µg/ml)

b. If deposit is a hybridoma, what is the isotype of the antibody produced? mIgG2a

8. Safety: Is this strain hazardous to humans? NO Animals? NO Plants? NO

If yes, what is the recommended biosafety level for working with this strain?

(Refer to *Biosafety in Microbiological and Biomedical Laboratories*, 4th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control. Washington, DC: U.S. Government Printing Office; 1999. The entire text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm.)

9. Regulatory Compliance:

a. Was the material derived from a human? Yes No
If yes, was an IRB-approved consent form (human subjects) obtained? Yes No

b. Was this material obtained from wildlife? Yes No
If yes, please indicate genus and species and whether wild or captive bred.

c. Is work performed at your facility with exotic viruses affecting livestock and avian species? Yes No

d. Identify any reagents of animal origin used to cultivate this organism/cell line (serum, growth factors, trypsin, etc.) and manufacturer, if known: FETAL BOVINE SERUM CERTIFIED. Origin : United STATES.
Mycoplasma, Virus, Bacteriophage, Endotoxin TESTED (INVITROGEN
Corporation)

10. Availability:

Prior to issuance of a U.S. Patent, ATCC will only make a culture available as instructed by the depositor or relevant patent office. Samples must be provided to a specific investigator if a pertinent Patent Office under the Budapest Treaty instructs ATCC to do so. The following questions must be answered:

a. As of date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to anyone who requests a culture? If yes, there are no restrictions on distribution. Answering no will ensure the deposit is not available until the patent has issued. Yes No

b. As of the date of deposit or conversion to meet the requirements of the Budapest Treaty, do you wish the deposit to be made available to requesters that satisfy Patent Offices in countries not signatory to the Budapest Treaty? Yes No
If "yes," please state which countries:

Please note that if you are converting your deposit to meet the requirements of the Budapest Treaty, and your deposit has already been released for distribution due to the issuance of a U.S. Patent, you cannot restrict it from further distribution. After a U.S. Patent issues and we are so notified, ATCC makes the culture available to anyone who requests it, as allowed under U.S. Patent and Trademark Office (USPTO) Rules and Regulations (37 CFR 1.808 [a][2]).

11. Notification: ATCC will notify you of your ATCC number after viability of the deposit has been confirmed.

Name of individual to notify: Joseph E. Panigot

Fax: 301-251-5321 Phone: 301-354-0696 E-mail: panigotj@macrogenics.com

12. Payment by check or credit card (MasterCard, VISA or American Express) must accompany the deposit unless prior arrangements for billing have been made and approved. ATCC accepts purchase orders for the exact amount.

Purchase Order No. _____

Check No. _____

Credit Card number. _____

MasterCard VISA American Express

Exp. Date: _____

Name shown on card: _____

(Please print clearly or type)

Signature of card holder: _____

PAYMENT: ATCC MUST HAVE A BILLING ADDRESS, CONTACT PERSON, PHONE AND FAX FOR ALL DEPOSITS:

Contact Name: Marilyn Maracic

Billing Address: Jones Day, 222 E. 41st Street
New York, NY 10017-6702

Phone: (212) 790-6417 Fax: (212) 869-9741

Do you have a current ATCC account number? Yes No

If Yes: ATCC Account Number = 178147

If No: To apply for an account with ATCC, please complete a New Account Application located on our Web site (www.atcc.org) and return it with supporting documentation to ATCC for approval.

13. Name, address, phone and fax number of your Attorney of Record.

Geraldine F. Baldwin, Esq.

Jones Day, 222 E. 41st Street

New York, NY 10017-6702

(Ref: Docket or Case No. 11183-013-999)

14. MUST BE COMPLETED. Deposited on behalf of: (Verify with your management who owns the deposit. The owner is usually a company or institution, and not an individual.)

MacroGenics, Inc.

I understand and agree that the deposit may not be withdrawn by me for the period specified in Rule 9.1 of the Budapest Treaty (at least 30 years after the date of deposit or 5 years after the date of the most recent request for the deposit, whichever is longer), and that if a culture should die or be destroyed during the life of the patent, or the period of time so specified, it is my responsibility to replace it with a living culture of the same organism or cell. In the cases of viruses, cell cultures, plasmids, embryos, and seeds, it is my responsibility to supply a sufficient quantity for distribution for the period of time specified above.

Joseph E. Panigot
Printed Name

Joseph E. Panigot
Signature

5/4/06
Date

Address. MacroGenics, Inc., 1500 East Guide Dr., Rockville, MD 20850

Phone: (301) 354-0666 Fax: (301) 251-5321 E-mail: panigotj@macrogenics.com

SHIPPING INFORMATION

BEFORE SHIPPING, PLEASE CONTACT THE ATCC PATENT DEPOSITORY FOR SHIPMENT ADVICE:

Fax: (703) 365-2745

E-mail: PatentDeposit@atcc.org

SHIPPING NOTICE:

The depositor is ultimately responsible for the shipment of deposits to ATCC and compliance with all applicable government regulations for the packaging and movement of the material. The depositor shall indemnify ATCC, to the extent permitted by law, against claims resulting from the violation of applicable government regulations caused by the depositor's shipment of deposits to ATCC.

STORAGE & FEES

Storage: Cultures are stored for 30 years from date of deposit or five years after the last request for a sample, whichever is longer, as required under the rules of patent offices in most countries.

Fees: All fees are subject to change. For current fees and other information, check our Web site at www.atcc.org or request a quotation of fees by e-mail at PatentDeposit@atcc.org or fax: (703) 365-2745.

ATCC USE ONLY: ATCC DESIGNATION DTA- 5962 REC'D 5/7/04 V.T. RESULT 5/25/04

ATCC® is a registered trademark of the American Type Culture Collection.

ATCC

505421-600001

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-365-2745

**BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.**

To: (Name and Address of Depositor or Attorney)

MacroGenics, Inc.
Joseph E. Panigot
1500 East Gude Drive
Rockville, MD 20850

Deposited on Behalf of: MacroGenics, Inc.

Identification Reference by Depositor:	Patent Deposit Designation
Hybridoma: 1D5	PTA-5958
Hybridoma: 1F2	PTA-5959
Hybridoma: 2D11	PTA-5960
Hybridoma: 2E1	PTA-5961
Hybridoma: 2H9	PTA-5962

The deposits were accompanied by: a scientific description, a proposed taxonomic description indicated above. The deposits were received May 7, 2004 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested May 25, 2004. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Marie Harris
Marie Harris, Patent Specialist, ATCC Patent Depository

Date: June 26, 2004

cc: Geraldine F Baldwin, Esq.
Docket or Case No.: 11183-013-999